Arterial chemoembolization with cisplatin microcapsules. by Okamoto, Y. et al.
Br. J. Cancer (1986), 53, 369-375
Arterial chemoembolization with cisplatin microcapsules
Y. Okamoto', A. Konnol, K. Togawal, T. Kato2, Y. Tamakawa3 & Y. Amano4
'Departments ofOtorhinolaryngology, 2Urology, 3Radiology and 4Central laboratory, Akita University School
ofMedicine, Akita 010, Japan
Summary Cisplatin (CDDP) was microcapsulated with ethylcellulose. Sustained release of CDDP from the
microcapsule, particularly non-protein-bound CDDP, which should have antitumour activity, was
demonstrated by an in vitro test. Using a bioassay, it was proven that the biological activity of CDDP was
not affected by the microencapsulation process.
When CDDP-mc were infused into the maxillary artery of patients with carcinoma of the maxillary sinus or
oral cavity, the CDDP level in the circulating blood was significantly lower than that of the patients given
non-encapsulated CDDP intravenously. However, a significantly higher CDDP concentration in tumour tissue
was found in patients treated with CDDP-mc.
These results suggest that selective arterial infusion of CDDP-mc could exert intensive topical antitumour
effects on lesions through microinfarction effects, and prolonged drug release, with minimum systemic side
effects.
Cisplatin (CDDP) is one of the most powerful anti-
neoplastic agents and response rates up to 40% in
patients with tumours of the testis or ovary, have
been demonstrated (Merrin, 1976). CDDP has also
been reported to be effective against carcinoma of
the head and neck (Wittes, 1977; Muggia, 1980).
However, it produces many side effects, such as
renal disturbance, vomiting, nausea and auditory
disturbance. Among these, renal disturbance is the
major problem.
Since antineoplastic agents have no selective
toxicity for cancer cells, effort should be
concentrated upon improving therapeutic efficacy
at the same time as minimizing side effects.
Using the conventional method of injecting drugs
into the artery serving the tumour, the agents flow
into the general circulation rapidly, and it is
difficult to keep in situ drug concentrations high.
Mitomycin-C microcapsule (Mitomycin-C, encap-
sulated with ethylcellulose) chemoembolization was
developed by Kato and colleagues (1979, 1981) who
showed a significant effect on tumours of the urinary
tract and liver.
In our study CDDP was encapsulated with
ethylcellulose and basic and clinical observations
recorded.
Materials and methods
Effect ofCDDP on L-cellproliferation
L-cells derived from mouse fibroblasts were
cultivated in MEM (Nishui Co., Ltd.) containing
10% foetal calf serum at 37°C.
After treatment with EDTA-trypsin, the cell
suspension was adjusted to 5 x 104/tube and
cultivated for 24h at 37°C. The culture media were
then exchanged with media containing CDDP
(Bristol Co., Ltd.) at various concentrations (0.05,
1.0, 5.0Mgml-1). Every 24h, viable cells were
counted, and growth rates determined.
CDDP was also preincubated with human serum
(CDDP lOpgml-l serum) for 24h at 37°C, and
added to the cells. The final CDDP concentration
in culture media was adjusted to 1 igmlP'.
Encapsulation of CDDP
CDDP was encapsulated with ethylcellulose by
using the method of coacervation with certain
modifications described for mitomycin-C micro-
capsules (Kato et al., 1978), and sterlilized at
1350C for 2h. CDDP-microcupsules (CDDP-mc)
consist of 60% (w/w) CDDP (Bristol Co., Ltd.) as
the core, and 40% (w/w) of ethylcellulose as the
shell. The dose of CDDP-mc was expressed as the
CDDP content. The particle size of CDDP-mc was
measured microscopically and the mean value was
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396 + 119 nm (Figure 1). The estimation of CDDP
from the microcapsule was examined as follows.
Human serum was drawn (2.5ml/lOmin) into a
Swinnex-13 with HA filter (Millipore Corporation)
containing lmg of CDDP-mc. The outflow was
collected by a fraction collector and the CDDP
concentration determined. During the experiment,
filter units were kept at 37°C in a water bath.
Figure 1 A microphotograph
( x 200) : 1OOPm.
of CDDP-microcapsule
Possible alteration of the biological activity of
CDDP follow the encapsulation process was
examined by the following two methods. Here, the
elution from CDDP-mc in saline was used to
evaluate the bioactivity of CDDP-mc.
In the first method (Rec assay) using Bacillus
subtilis inhibition of the H-17 (Rec+) strain was
compared with the M-45 (Rec-) strain (Sadaie et
al., 1976). Briefly, bacterial suspensions were
streaked, in the shape of the letter 'V' on nutrient
agar plates (see Figure 5). A paper disc (8mm in
diameter) dipped with CDDP or CDDP-mc (each
concentration, 0.5mg) was placed on the apex of
the 'V'. The plates were incubated overnight at
37°C and bacterial growth was determined.
In the second method, Pseudomonas aeruginosa
was used to determine CDDP-mc activity. Pseud.
aeruginosa harvested from nutrient agar plates was
cultivated in nutrient broth for 8h at 37°C and was
used as a seed culture. An aliquot (O.1ml) of seed
culture was added to each test tube (18 x 180 mm)
containing 5ml of broth and CDDP or CDDP-mc
at various concentrations. The tubes were incubated
at 37°C, under gentle shaking. At certain times
after incubation, the turbidity of each tube was
measured at 600 nm.
Clinical study
A polyethylene catheter was percutaneously inserted
into the femoral artery of patients with maxillary or
oral cancer through a stab wound under local
anaesthesia and guided to the external carotid
artery by fluoroscopic monitoring.
CDDP-mc suspended in saline (- 60mg per
60ml) was infused into the maxillary artery or the
lingual artery.
During infusion, the superficial temporalis artery
was pressed at the preauricular region to prevent
inflow of CDDP-mc.
After administration of the drug, blood samples
were collected at various time intervals and total
urine collections were made for 7 days in order to
determine the CDDP concentration.
Biopsies were performed on 5 patients with
maxillary cancer at 1 h, 3 days and 7 days after
administration. The biopsied specimen was
homogenized in saline containing 1:1000 of Triton
X-100 and the final concentration of homogenate
was adjusted to 1:2 (w/v). The total platinum level
was then determined.
As controls, patients with maxillary cancers were
given non-encapsulated CDDP. CDDP 60mg was
administered to 3 patients by continuous peripheral
i.v. infusion over 24h, and 20mg CDDP was
administered into the maxillary artery of 3 patients
in 5mmn.
The patients, given unencapsulated CDDP or
CDDP-mc were hydrated with 2000ml saline prior
to the drug administration and hydration was
maintained for 7 days after the administration in
order to increase urine output.
The quantity of CDDP in the clinical specimen
was determined by a Perkin-Elmer model 403
atomic absorption spectrophotometer with heated
graphite atomizer (HGA 2100). The sample 20Ml
was applied to the atomizer and dried for 60sec at
150°C, charred for 60sec at 1500°C (1900°C for
biopsy specimen), and atomized at 2700°C for
15sec. CDDP concentration was calculated from
the platinum concentration.
Non protein-bound-CDDP concentration in the
serum was determined after ultrafiltration by
Centriflo CF-50A (Amicon Co., Ltd.).
Results
Effect ofCDDP on the growth ofL cells
Figure 2 shows the proliferation of L cells under
various concentrations of CDDP. Cell proliferation
was inhibited at lgml-l of CDDP and the cell
number decreased after 48 h of incubation with
5 ggml -1 of CDDP.
CDDP incubated with human serum did not
show any effects on cell growth (Figure 3).CISPLATIN MICROCAPSULE CHEMOEMBOLIZATION 371
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Figure 3 Effect of CDDP incubated with human
serum on L-cell proliferation. Inhibitory action was
not observed. (0) control; (0) CDDP+serum.
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Figure 2 Proliferation of L-cell and CDDP concen-
tration. Proliferation was inhibited at 1 jgml -1 of
CDDP and cell number decreased after 48h of
incubation with 5pgml-1 of CDDP. (0) control; (A)
0.05ygml- 1 CDDP; (V) 1.0ygml-1 CDDP; (U)
5.0 tgml-1 CDDP.
Elution ofCDDPfrom microcapsule
By in vitro tests, elution of CDDP from
microcapsules was rapid during the first few hours,
then the elution speed gradually decreased.
However, a low level of elution lasted many hours
and the CDDP level was 300ngm1-1, at 38h from
beginning the experiment. The protein-bound-
CDDP level in the eluate is proportional to the
total CDDP of the eluate (Figure 4).
The results of the Rec assay are shown in Figure
5. CDDP inhibited growth of the Rec- strain but
not the Rec+ strain, and no difference was found in
the activities of CDDP and CDDP-mc.
Growth of Pseud. aeruginosa was partially
inhibited by 1.0 pgml- of CDDP, but no
difference was found between CDDP and CDDP-
mc.
Clinical study
The CDDP blood concentrations of patients who
had received 60mg of CDDP-mc are shown in
Figure 6. Highest levels were detected 1-2 days
after administration, then gradually decreased. All
CDDP found in the blood was protein-bound.
CDDP concentrations in the biopsied cancer
tissue taken from patients with maxillary tumours,
who had been given 60mg of CDDP-mc, are shown
in Figure 7. The peak concentration in the tissues
was found 3 days after drug administration, and
the maximum level in each patient was 30-
150Mgg 1 wet tissue.
CDDP levels in the blood of patients who had
been administered with 60mg of non-encapsulated
CDDP by continuous infusion over 24h reached
the maximum (2800ugml-1) just after completion
of the infusion, and then decreased gradually
(Figure 8). Non protein-bound CDDP was
detectable for only 2h after infusion.
When 20mg CDDP was administered into the
artery, CDDP concentrations reached 2700-
3200ngml-1 in blood and 0.3-7.Opgg-1 (wet
tissue) in specimens just after infusion. However,
they both decreased rapidly. Non protein-bound
CDDP was detectable in blood for the 2h period
following infusion.
The urinary excretion study of CDDP, after the
administration of CDDP-mc, showed that 6-12.5%
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Discussion
Cisplatin (cis-dichlorodiamine platinum (II),
CDDP) is a water-soluble compound which has a
platinum atom in the centre with 2 chlorine and 2
ammonia atoms located at the cis position.
Rosenberg (1965) found that coli bacilli lost their
splitting ability and formed a long filament in a
solution using a platinum electrode. This
observation led to the disclosure of the antibacterial
effect, and subsequently the anti-tumour effect of
platinum.
The anti-tumour effect of various platinum
compounds has since been studied, with the
eventual discovery of CDDP.
Since then clinical applications of CDDP were
commenced and with the recognized effectiveness of
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Figure 5 Rec assay of CDDP and CDE
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and no difference was found in the activi
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(mean, 6.8%) of the total was dete
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)P-mc. CDDP become a popular anti-tumour drug (Merrin, 1976;
t Rec+ strain, Wittes, 1977; Muggia, 1980).
ities of CDDP However, some side effects such as renal,
digestive tract and auditory disturbances, have
arisen as difficult problems.
The anti-cancer action of CDDP depends on an
zctable within affinity for DNA, though CDDP also possesses an
7 days. affinity for protein. When administered in vivo,
)DP i.v. 15- CDDP is quickly bound to albumin and the
in 24h, while gamma-globulin in the blood to form protein-
bound CDDP. But as shown in Figure 3, protein-
4800
4200
3600
- 3000
cm
c 2400 a-
a 0
1800
1200
600CISPLATIN MICROCAPSULE CHEMOEMBOLIZATION 373
EI
CD cn
0
u
Time (d) after administration
Figure 6 CDDP concentration in the blood of patients administered 60mg of CDDP-mc (n=8).
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Figure 7 CDDP concentration in biopsied cancer tissue
of patients given 60mg CDDP-mc (0) (n=5), or
20mg CDDP intraarterially (A) (n=3).
bound type has no inhibitory action on cell
proliferation in vitro.
It is unlikely that dissociation occurs easily once
CDDP is bound to protein. Therefore, carcino-
static effects cannot be expected of the protein
bound type CDDP remaining at high concentrations
in the blood over a long period of time after
TT
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Figure 8 CDDP concentration in blood ofthe patients
given 60mg non-encapsulized CDDP i.v. (0) (n=3)
or 20mg intraarterially (0) (n=3). Dotted line shows
non-protein-bound CDDP.
completion of drip infusion as shown in Figure 8.
Lowering the concentration is of help in reducing
the side effects.
By arterial injection of CDDP even at a dose ofvwww374 Y. OKAMOTO et al.
Figure 9 A 69-year old woman with carcinoma of
hard palate. Tumour before (above) and 3 weeks after
(below) administration of CDDP-mc (60mg). Marked
shrinkage is evident.
Microcapsules introduced into an artery serving
the tumour region, easily cause embolism in the
region because of their size. Hopefully, embolism
would suppress the growth of the tumour.
The time-releasing property of the microcapsule
is realised by the fact that a drug coated with
ethylcellulose dissolves in the blood stream over a
period of hours.
Combining these two principles, anti-cancer
drugs can theoretically be administered to a tumour
with greater specificity and efficacy. Moreover, if it
is possible to maintain a high drug concentration in
tumour only, their systemic side effects can be
greatly reduced.
However, microcapsules containing mitomycin-C
have been reported to cause occasionally incurable
skin ulcers as a side effect (Kato et al., 1981). The
use of this drug, therefore was contraindicated for
tumours of the head and neck.
In the present report, the efficacy of CDDP-mc
was studied in the following areas: biological
activity of CDDP eluted from CDDP-mc, CDDP
Table I The cases in which CDDP-mc (40-60mg) alone was injected as the initial treatment
Name Treatedsites TNM Histology Response
1 K.T. Maxillary sinus T4NOMO Squamous carcinoma PR
2 T.T Maxillary sinus T4NOMO Squamous carcinoma PR
3 G.K. Maxillary sinus T4NOMO Adenoid cystic carcinoma MR
4 M.I. Maxillary sinus T3NOMO Squamous carcinoma Stable
5 S.S. Nasal cavity T3NOMO Squamous carcinoma PR
6 T.S. Nasal cavity T4AMO Squamous carcinoma MR
7 S.S. Nasal cavity T4NOMO Squamous carcinoma MR
8 J.S. Nasal cavity T3NOMO Malignant melanoma PR
9 T.K. Oral cavity T2NOMO Anaplastic carcinoma CR
10 K.T. Oral cavity T3NOMO Squamous carcinoma PR
11 S.S. Oral cavity T2NOMO Squamous carcinoma CR
12 R.Y. Oral cavity T3NOMO Squamous carcinoma MR
13 K.O. Oral cavity T2NOMO Squamous carcinoma PR
14 H.S. Oral cavity T2NOMO Squamous carcinoma PR
PR=partial response; CR=complete response; MR=minimal response.
20mg, blood concentrations were very high. To
increase the dose is dangerous because the blood
CDDP concentrations are reportedly correlated
with renal disturbance (Campbell et al., 1981).
Accordingly we have evaluated microcapsule
embolization containing CDDP. Microcapsule
containing mitomycin-C developed by Kato et al.
(1979; 1981), have been recognized as a unique
form of chemotherapy of tumours of the urinary
tract and liver. The microcapsule acts on two basic
principles: tumour vessel embolism, and time-
releasing properties.
concentration in cancer tissue, and responses and
side effects after the administration of CDDP-mc.
CDDP is a fairly stable compound when exposed
to heat, light, and pH variations (Galabres et al.,
1975). The biological activity of eluted CDDP from
sterilized CDDP-mc was determined by the Rec
assay and cell growth inhibition test.
As seen in Figure 5, CDDP eluted from
microcapsules showed similar activity to the
starting CDDP and it is clear that the biological
activity of CDDP can be preserved completely,
even after the microcapsulization process.CISPLATIN MICROCAPSULE CHEMOEMBOLIZATION 375
The elution speed of CDDP from the
microcapsule, determined by an in vitro system,
showed a biphasic profile. In the first phase, the
CDDP concentration in the eluate decreased
quickly, from 4,900ngml-1 to 1,800ngml-1 in 6h.
In the second phase, CDDP concentration
decreased gradually, from 1,800ngml1 to
460ngml-1 in 32h.
When the blood CDDP concentration after
administration of CDDP-mc was examined, it
reached a peak 1-2 days later and its value was
600-1,400ngml-1. These cases account for I of
the cases where an equivalent dose of CDDP was
administered by drip infusion.
Using 60mg of CDDP-mc, the Pt concentration
in biopsied cancer tissue reached its peak, which
was 30-150igg-1 (wet weight). This was arrived at
3 days after administration, and gradually
decreased.
With arterial infusion of 20mg non-encapsulized
CDDP, the CDDP concentration in blood was very
high (2,700-3,200ngml-1) but not in cancer tissue
(3,000-7,000ngg -1).
Using 100mg of ordinary CDDP i.v. Mattox et
al. (1983) reported that the CDDP concentration in
the cancer tissue was 1.5 gg-1, 2h, and 9.9pgg-
6h after injection.
The above results can not be compared.
However, drug concentrations in target tissue can
be kept at a higher level by the microcapsule
technique than by the conventional administration
technique. Especially, with the usual method of
injection into the artery serving the neoplastic
region, CDDP flows rapidly into the general
circulation, making it difficult to keep the
concentration high in the tumour.
Next, cases were presented in which only CDDP-
mc (40-60mg) was injected intra-arterially as an
initial treatment (Table I).
Of 14 patients, 9 subsequently had a marked
tumour reduction of over 50% in measurable
diameter (e.g. Figure 9). In addition to these cases,
7 cases who had received or were receiving
radiation were treated with CDDP-mc.
Considering side effects, nausea and vomiting
were observed in 12 out of the 21 cases. In none
however, was renal hypofunction observed by either
the PSP or the creatinine clearance tests. Buccal
pain on the affected side was a common complaint
in 14 cases. This, however, mostly controllable
by the administration of an analgesic, and
symptoms disappeared within 24h. Auditory
disturbance was not detected.
Thus, selective intra-arterial injection of CDDP-
mc could make it possible to treat cancers
continuously and selectively, raising hopes that the
therapeutic effect will be increased and the general
side effects ofCDDP reduced.
The authors thank Dr. Katsuo Unno and Dr. Akio Goto
for their technical assistance in preparing the micro-
capsules.
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